- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles1 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HALO Market Currents
more »
-
May 7 Halozyme Therapeutics (HALO): Q1 EPS of $0.14 beats by $0.25. Revenue of $7.4M (-1.3% Y/Y) in-line. (PR)
Comment![Earnings, Healthcare]
HALO in Focus
more »
HALO Related Articles
more »
HALO News
more »
-
at CNBC.com (Jan 18, 2012)
-
at MarketWatch.com (May 7, 2010)
HALO Press Releases and Filings
more »
-
PR Newswire (May 9, 2012)
-
PR Newswire (May 7, 2012)
-
PR Newswire (Apr 30, 2012)
-
PR Newswire (Apr 16, 2012)
-
PR Newswire (Dec 7, 2011)
HALO Latest Transcript
more »
HALO Cramer
more »
HALO Instablog posts
more »
HALO vs. ETF Alternatives
Company Description
Currently, there's no company description for HALO.
